Eva Gimeno, MD

Department of Hematology, Hospital del Mar, Spain

N/A

Poster(s):

• 1152 - Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients